Britain and America have signed a key bilateral deal that will preserve zero duties on UK medicine exports entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital goods will remain at nothing for a duration of three years.
This deal is in response to earlier threats to dramatically increase duties on patented drug products, with increases floated up to 100%.
"This arrangement with the UK bolsters the worldwide climate for new treatments and introduces long-overdue balance to American-British drug exports," a release noted.
Trade Impact
Drugs are one of the UK's biggest goods shipped to the US, which is clearly the primary market for large UK drugmakers.
Export figures indicate that in the 12 months prior to September, the UK shipped medicines worth £11.1bn to the US. This figure represented 17.4% of total UK exports in that period.
"This deal safeguards employment, increases investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific NHS Changes
The pact includes several notable changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. In the past, rebates exceeded twenty percent.
Industry Background
The deal comes amid a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were heightened by arguments that US patients were paying significantly more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been paused or abandoned, while major expansions have been directed toward US facilities.
One official publicly accepted that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
